Dr. Elizabeth Thompson is Acadia’s Executive Vice President, Head of Research and Development where she leads the R&D organization in the development of new products in rare and central nervous system disorders and other opportunities to expand our pipeline of medicines. She joined Acadia in April 2024. View All Management Team
Dr. Thompson served most recently as Executive Vice President, Research and Development (Rare Disease) at Amgen following its acquisition of Horizon Therapeutics plc. At Horizon, Dr. Thompson served in roles of increasing responsibility including as Executive Vice President, Research and Development at the time of Horizon’s acquisition. Prior to joining Horizon, she was with AbbVie as Group Scientific Director, Clinical Development and, before that, Senior Scientific Director, Clinical Development. Before AbbVie, Dr. Thompson held roles at Raptor, InterMune and Amgen in a career spanning clinical development, business development and medical communications.
Dr. Thompson received a Bachelor of Science degree in Chemistry from Harvey Mudd College and a Doctorate in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute.